Navigation Links
EntreMed to Present at BioPartnering Europe Conference
Date:10/10/2008

ROCKVILLE, Md., Oct. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that Thomas H. Bliss, Jr., EntreMed's Senior Vice President, Corporate and Business Development, will present a Company overview at the 16th Annual BioPartnering Europe Conference, which is being held October 12-14, 2008 in London, United Kingdom. Mr. Bliss' presentation is scheduled for Monday, October 13, 2008 at 12:15 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Bliss will provide an overview of the Company's clinical-stage programs, with particular emphasis on ENMD-2076 and 2ME2 for rheumatoid arthritis. ENMD-2076, an orally-active, Aurora/angiogenesis inhibitor for the treatment of cancer, is in a multi-center Phase 1b dose-escalation study in patients with solid tumors. Panzem(R) (2ME2), an orally-active small molecule angiogenesis inhibitor with disease modifying properties for the treatment of rheumatoid arthritis (RA), has completed a Phase 1 clinical trial in healthy volunteers. EntreMed is actively marketing ENMD-2076 and 2ME2 for RA to prospective pharmaceutical and biotech company partners as a means to accelerate the development and commercialization of these novel drug candidates.

Mr. Bliss's presentation will not be web cast; however, a copy of his presentation will be available through the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical compa
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
2. EntreMed Reports Second Quarter 2008 Financial Results
3. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
6. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
7. EntreMed Receives Nasdaq Deficiency Notice
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Announces 2008 Corporate and Clinical Program Priorities
10. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
11. EntreMed to Present at BIO CEO and Investor Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... The two humanitarian organiza...rograms, including biomedical repair technologies....t the West African country of Togo. , ...- With the recent signing of a Memorandum of Under...ave formalized a partnership to help develop susta...
(Date:11/30/2009)... , COLUMBUS, Ohio, Nov. 30 Th...for one of the nation,s first minority business ea...in Cleveland December 3, is called "Transforming t...siness Early-Stage Capital Summit." It will featur...inority business leaders and local minority entrep...
(Date:11/30/2009)... , NEW YORK, Nov. 30 /PRNewswire-USNewswire/ ...esearch (MJFF) today announced $1.5 million in tot... potentially disease-modifying therapies for Parki... Novel Approaches to Drug Discovery for Parkinson,...Elan Corporation, plc (NYSE: ELN ), a neuroscien...
(Date:11/30/2009)... , CHICAGO, Nov. 30 Dr. Jessica...rge Washington University Medical Center in Washin...f Breast-Specific Gamma Imaging (BSGI) in clinical...iagnosis of breast cancer today at the annual meet...RSNA). ,, "The purpose of the exhibit was to de...
Breaking Biology Technology:Mercy Ships and MediSend International Partner to Deliver Hope and Healing 2Mercy Ships and MediSend International Partner to Deliver Hope and Healing 3Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2
...ial Bank Loan With Interest Payment Subsidy, BEIJ... Ltd. (Amex:,SVA), a vaccine-focused biotech compa...gguancun Enterprises Credit Promotion Association ...ganized an annual Business,Credit Rating program. ...s,("the Company") credit rating was successfully u...
...Help Commonwealth Care Alliance,Coordinate Care an...et, Inc., a provider of,innovative care management...alth Care Alliance, a not-for-profit care delivery...ution to more effectively manage its,members, care...ommunication,between direct care providers and Com...
...chnology, scientists have used a wide variety of m...t as in the construction business, nanotechnology ...raw materials. Now, Biodesign Institute at Arizona...hese pitfalls by using cells as factories to make ...The results were published in the early online edi...
Other Biology Technology:Sinovac's Credit Rating Upgraded to AAZ, Second Highest Rating 2Sinovac's Credit Rating Upgraded to AAZ, Second Highest Rating 3Commonwealth Care Alliance Selects Casenet To Unify Patient Information and Improve Care for Massachusetts Members 2Commonwealth Care Alliance Selects Casenet To Unify Patient Information and Improve Care for Massachusetts Members 3Using living cells as nanotechnology factories 2Using living cells as nanotechnology factories 3
(Date:12/1/2009)...s disease, nerve cell degeneration plays a crucial...possibly be derived from steering the generation a...n published in the current issue of the renowned j...rs ago, neurogenesis the process of nerve cell de...adult brain. The textbooks asserted that dead nerv...
(Date:12/1/2009)... University cancer researchers have developed a t...ells and blocks the growth of new tumor blood vess...d to kill cancer cells oncolytic viruses might b...f they also carry a gene for a protein that inhibi...culostatin, is normally produced in the brain. In ...
(Date:12/1/2009)...f the 2009 Inserm Grand Prix., Every year since ... tribute to outstanding,work performed in its lab...nserm intends to,demonstrate the diversity and we... medical and,health research, and the creativity ...,drive this research each day. The Inserm 2009 pr...
Breaking Biology News(10 mins):New source discovered for the generation of nerve cells in the brain 2Tumor-attacking virus strikes with 'one-two punch' 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 3e Telmed Inc the Leading Telehealth Solution Provider Signs Exclusive Agreement with Synergistic Healthcare 55749 1e Telmed Inc the Leading Telehealth Solution Provider Signs Exclusive Agreement with Synergistic Healthcare 55749 2VirtualScopics to Present at the Rodman 26 Renshaw Annual Global Investment Conference 55746 1VirtualScopics to Present at the Rodman 26 Renshaw Annual Global Investment Conference 55746 2New National Poll Finds Americans Strongly Opposed to Cutting Medicare Payments for Nursing Home Care as a Means of Financing Health Care Reform 55742 1New National Poll Finds Americans Strongly Opposed to Cutting Medicare Payments for Nursing Home Care as a Means of Financing Health Care Reform 55742 2New National Poll Finds Americans Strongly Opposed to Cutting Medicare Payments for Nursing Home Care as a Means of Financing Health Care Reform 55742 3New National Poll Finds Americans Strongly Opposed to Cutting Medicare Payments for Nursing Home Care as a Means of Financing Health Care Reform 55742 4
...g cause of nearly twice as many infant deaths than... by researchers at the U.S. Centers for Disease Co...day in Pediatrics, found that in 2002 preterm birt..., contributed to more than one-third of infant dea...ng known that babies born too soon face many chall...
...tute of Virology and Immunology (GIVI) have identi...G), a protein that acts against HIV, a finding tha...nfection. , The work is published today, Oct. 2,...ciences, USA. , The research, conducted by scien... Greene, MD, PhD, explains why CD4 T cells ?the im...
...ements in the end-of-life care in intensive care u...cial supplement to Critical Care Medicine, the jou... supplement is dedicated entirely to end-of-life c... quality of care received by critically ill and dy...ge," explains guest co-editor J. Randall Curtis, M...
Other Biology News:New study: Preterm birth causes one-third of all infant deaths 2Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G 2End-of-life care can be improved 2End-of-life care can be improved 3
...ing Sets contain the basic components and protocol...ISA plates for quantitation of a specific protein ...eening Set contains Coating and Detection Antibodi... Streptavidin-HRP, TMB Substrate Solution (one-ste...
Organic Acid Analysis Standard, 6 vials from Bio-Rad
... a particle shape and size analyzer offering a wid...ost simplicity in mind. It is comprised of a chemi...ical bench. The system is completely computer cont... for different applications such as dry or where s...
Neurological Profile from Novascreen-a Caliper Life Sciences Company
Biology Products: